Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Mutation”

252 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 252 results

Testing effectiveness (Phase 2)UnknownNCT05340413
What this trial is testing

Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.

Who this might be right for
HER2-negative Breast CancerMetastatic Breast CancerTriple Negative Breast Cancer
SOLTI Breast Cancer Research Group 63
Testing effectiveness (Phase 2)UnknownNCT05135715
What this trial is testing

RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)

Who this might be right for
Melanoma, Stage IIHER2-positiveAdvanced Melanoma
RemeGen Co., Ltd. 50
Early research (Phase 1)Looking for participantsNCT06488378
What this trial is testing

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

Who this might be right for
Breast CancerPALB2-Mutated Breast CarcinomaHER2-negative Breast Cancer+2 more
Dana-Farber Cancer Institute 20
Not applicableLooking for participantsNCT06805812
What this trial is testing

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

Who this might be right for
Breast AdenocarcinomaBreast Cancer Stage IVBreast Cancer, Metastatic+38 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 3,500
Large-scale testing (Phase 3)Active Not RecruitingNCT05646862
What this trial is testing

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Who this might be right for
Breast Cancer
Hoffmann-La Roche 420
Testing effectiveness (Phase 2)Study completedNCT01827267
What this trial is testing

Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer

Who this might be right for
HER2-mutant Non-Small Cell Lung Cancer
Puma Biotechnology, Inc. 62
Early research (Phase 1)Study completedNCT02260661
What this trial is testing

Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours

Who this might be right for
Advanced Solid MalignanciesBreast Cancer - ER+, HER2 -Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation
AstraZeneca 20
Not applicableStudy completedNCT03590938
What this trial is testing

Lynparza Breast Cancer Clinical Experience Investigation

Who this might be right for
Breast Cancer
AstraZeneca 111
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06185400
What this trial is testing

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Who this might be right for
Non Small Cell Lung CancerERBB2 Mutation-Related TumorsERBB2 Gene Duplication+1 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 108
Testing effectiveness (Phase 2)Study completedNCT02979821
What this trial is testing

Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)

Who this might be right for
HER2 Gene MutationAdenocarcinoma Lung Stage IV
Korean Association for the Study of Targeted Therapy 6
Testing effectiveness (Phase 2)Looking for participantsNCT05315700
What this trial is testing

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Who this might be right for
Solid Tumors
ORIC Pharmaceuticals 350
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05350917
What this trial is testing

Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy

Who this might be right for
HER2-positive or Mutated Advanced Colorectal Cancer
The First Affiliated Hospital of Zhengzhou University 20
Early research (Phase 1)WithdrawnNCT04602117
What this trial is testing

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Who this might be right for
HER2-positive Breast CancerHER2 LowSYD-985+24 more
QuantumLeap Healthcare Collaborative
Large-scale testing (Phase 3)Active Not RecruitingNCT05063786
What this trial is testing

Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)

Who this might be right for
Advanced Breast Cancer
Spanish Breast Cancer Research Group 27
Early research (Phase 1)Study completedNCT06348888
What this trial is testing

Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants

Who this might be right for
Advanced Non-small Cell Lung CancerEGFR MutationHER2 Mutation+1 more
Bayer 30
Not applicableUnknownNCT04368442
What this trial is testing

Cohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic Mutation

Who this might be right for
Breast Cancer Metastatic
Samsung Medical Center 583
Testing effectiveness (Phase 2)Looking for participantsNCT05768139
What this trial is testing

First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Who this might be right for
Breast CancerSolid Tumors, Adult
Eli Lilly and Company 720
Testing effectiveness (Phase 2)Study completedNCT03845270
What this trial is testing

Her2-positive Lung Cancer Treated With Dedicated Drug

Who this might be right for
Non Small Cell Lung Cancer MetastaticNon Small Cell Lung Cancer Stage IIIHER2 Gene Mutation
Intergroupe Francophone de Cancerologie Thoracique 46
Early research (Phase 1)Active Not RecruitingNCT03983954
What this trial is testing

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

Who this might be right for
ER+ Breast CancerOvarian CancerCervical Squamous Cell Carcinoma+17 more
NeoTX Therapeutics Ltd. 120
Testing effectiveness (Phase 2)Study completedNCT04240106
What this trial is testing

Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)

Who this might be right for
Breast CancerBreast Cancer Metastatic
MedSIR 14
Load More Results